Abramson Cancer Center at Penn Medicine clinical trial pipeline

17 trials changed in the last 30 days: 0 stopped, 10 with notable changes, 7 with minor changes only.

1. Notable

   Neoadjuvant PD-1 Blockade · Stage IIB/C Melanoma

   Primary completion pushed from Dec 1, 2024 to Nov 13, 2025

   Also in this update: Final enrollment: 86 participants (planned 63)

   Abramson Cancer Center at Penn Medicine·Phase 2· NCT03757689· Registry history of NCT03757689 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

2. Notable

   Limited-duration Teclistamab

   Primary completion pushed from Jun 2026 to Jan 2027

   Also in this update: Completion pushed from Jan 2027 to May 2027

   Abramson Cancer Center at Penn Medicine·Phase 2· NCT05932680· Registry history of NCT05932680 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

3. Notable

   BCG at Home · Intravesical Treatment of Bladder Cancer at Home…BCG at Home · Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

   Primary completion pushed from Aug 5, 2026 to Feb 5, 2027

   Also in this update: Completion pushed from Sep 5, 2026 to Apr 5, 2027

   Abramson Cancer Center at Penn Medicine·Not applicable· NCT07048496· Registry history of NCT07048496 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

4. Notable

   Autoimmunity After Checkpoint Blockade

   Primary and study completion pushed from Jun 30, 2026 to Feb 24, 2030

   Abramson Cancer Center at Penn Medicine·Not specified· NCT04119713· Registry history of NCT04119713 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

5. Notable

   SENTINEL · Hypertension and Arrhythmias in CLL Patients Treated…SENTINEL · Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

   Primary and study completion pushed from Aug 2026 to Jun 2027

   Abramson Cancer Center at Penn Medicine·Not specified· NCT06211413· Registry history of NCT06211413 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

6. Notable

   AGE-ING · Geriatric Evaluations Impact on New AML Guidance

   Primary and study completion pushed from Dec 1, 2026 to Dec 1, 2027

   Abramson Cancer Center at Penn Medicine·Not specified· NCT05909501· Registry history of NCT05909501 on ClinicalTrials.gov (opens the registry)

   Updated Oct 2, 2026

7. Notable

   Zr89 + PET Companion Trial

   Primary completion pushed from Dec 18, 2025 to Jul 30, 2026

   Also in this update: Completion moved earlier from Dec 18, 2027 to May 12, 2027; and 2 more changes in the last 30 days

   Abramson Cancer Center at Penn Medicine·Early Phase 1· NCT05279027· Registry history of NCT05279027 on ClinicalTrials.gov (opens the registry)

   Updated Sep 21, 2026

8. Notable

   CAR-T Followed by Bispecific Antibodies

   Primary endpoint(s) modified

   Also in this update: Enrollment closed, study ongoing

   Abramson Cancer Center at Penn Medicine·Phase 2· NCT04889716· Registry history of NCT04889716 on ClinicalTrials.gov (opens the registry)

   Updated Sep 14, 2026

9. Notable

   Consolidative Metastasis and Primary Directed Therapy (MPDT) for…Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

   Recruitment opened

   Abramson Cancer Center at Penn Medicine·Not applicable· NCT06770855· Registry history of NCT06770855 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

10. Notable

    Improving Utilization of Supplemental Breast MRI Screening…Improving Utilization of Supplemental Breast MRI Screening · Extremely Dense Breasts

    Results posted: Oct 2, 2026

    Abramson Cancer Center at Penn Medicine·Not applicable· NCT05787249· Registry history of NCT05787249 on ClinicalTrials.gov (opens the registry)

    Updated Oct 2, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.